Aurion Biotech (AURN) has filed for a proposed IPO.
The company describes itself as: "We are a clinical-stage biotechnology company committed to developing and commercializing disease-modifying, regenerative therapies to restore vision to millions of patients worldwide. We are advancing a single administration, allogeneic cell therapy to treat vision loss due to corneal endothelial diseases. In Japan, our first-generation cell therapy product, HCEC-1, received regulatory and reimbursement approval, and launched commercially in September 2024 under the marketed name Vyznova. Our next-generation product candidate, AURN001, is an improved formulation designed to be mechanistically identical to Vyznova and to provide enhanced benefits, including manufacturing scalability and extended shelf life. We believe AURN001 has the potential to serve as a first-line therapy for patients with corneal edema secondary to corneal endothelial dysfunctions. AURN001 has been developed leveraging data generated globally across five completed clinical trials in 154 procedures in 130 subjects, including four trials evaluating HCEC-1 and one trial evaluating AURN001. Across these completed trials, subjects experienced clinically meaningful and sustained improvements in anatomical and functional measures of corneal health, central corneal thickness (“CCT”) and best corrected visual acuity (“BCVA”), respectively. In addition, we have completed enrollment and dosed 97 subjects in a Phase 1/2 clinical trial for AURN001 in the United States and Canada, and 12-month data from this trial is expected in the second half of 2025."
J.P. Morgan, BofA Securities, Piper Sandler and Wells Fargo (NYSE:WFC) Securities will serve as underwriters.